Kimberly Commins-Tzoumakas biography
Kimberly J. Commins-Tzoumakas J.D. serves as Independent Director of the Company. Since January 2018, Ms. Commins-Tzoumakas has served as Chief Executive Officer of 21st Century Oncology, a global provider of integrated cancer care services, transitioning from interim CEO to permanent CEO in April 2018. From November 2014 to January 2018, she served as its General Counsel and as a member of its leadership team. From November 2001 to April 2018, Ms. Commins-Tzoumakas practiced health care law with Hall Render Killian Heath & Lyman, providing strategic, transactional and governance advice to health care clients throughout the country. While at Hall Render, she was also a long-term managing partner of the firm's Michigan office and a board member of the firm. Ms. Commins-Tzoumakas received a B.A. in business administration from Northwood University and a J.D. from the Thomas M. Cooley Law School.
What is the salary of Kimberly Tzoumakas?
As the Independent Director of SeaSpine Corp, the total compensation of Kimberly Tzoumakas at SeaSpine Corp is $243,750. There are 9 executives at SeaSpine Corp getting paid more, with Keith Valentine having the highest compensation of $1,840,570.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
How old is Kimberly Tzoumakas?
Kimberly Tzoumakas is 52, she's been the Independent Director of SeaSpine Corp since 2019. There are 10 older and 10 younger executives at SeaSpine Corp. The oldest executive at SeaSpine Holdings Corp is Keith Bradley, 75, who is the Independent Director.
What's Kimberly Tzoumakas's mailing address?
Kimberly's mailing address filed with the SEC is COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY, CA, 94065.
Insiders trading at SeaSpine Corp
Over the last 9 years, insiders at SeaSpine Corp have traded over $2,659,931 worth of SeaSpine Corp stock and bought 297,805 units worth $3,591,897 . The most active insiders traders include Stuart Essig, Richard E Caruso és Keith Valentine. On average, SeaSpine Corp executives and independent directors trade stock every 39 days with the average trade being worth of $151,762. The most recent stock trade was executed by John J. Winge on 1 January 2023, trading 4,868 units of SPNE stock currently worth $46,441.
What does SeaSpine Corp do?
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine's orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine's spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide.
What does SeaSpine Corp's logo look like?
SeaSpine Corp executives and stock owners
SeaSpine Corp executives and other stock owners filed with the SEC include:
-
Keith Valentine,
President, Chief Executive Officer, Director -
Keith C. Valentine,
Pres, CEO & Director -
John Bostjancic,
Chief Financial Officer, Senior Vice President, Treasurer -
Tyler Lipschultz,
Senior Vice President, Orthobiologics and Business Development -
Patrick Keran,
Vice President, General Counsel, Secretary -
John Winge,
Vice President of Sales -
John J. Bostjancic,
Sr. VP, CFO & Treasurer -
Patrick L. Keran,
Sr. VP, Gen. Counsel & Sec. -
Dr. Beau Standish P.Eng., Ph.D.,
Pres of Enabling Technologies -
Kimberly Commins-Tzoumakas,
Independent Director -
Renee Gaeta,
Independent Director -
Kirtley Stephenson,
Independent Non-Executive Chairman of the Board -
Stuart Essig,
Lead Independent Director -
Michael Fekete,
Independent Director -
Keith Bradley,
Independent Director -
John Henneman,
Independent Director -
Dennis Cirino,
Senior Vice President, Global Spinal Systems -
Hollis Winkler,
Sr. VP of HR -
Patrick L. Keran J.D.,
Sr. VP, Gen. Counsel & Sec. -
Dr. Frank Vizesi,
Chief Scientific Officer -
Shaeffer Bannigan,
Sr. Director of Product Devel. -
Paul Benny,
VP, Corp. Controller, Assistant Treasurer & Assistant Sec. -
Dr. Beau Standish Ph.D.,
Pres of Enabling Technologies -
Dennis L. Cirino,
Sr. VP of Global Spinal Systems -
Tyler P. Lipschultz,
Sr. VP of Orthobiologics & Bus. Devel. -
John J. Winge,
VP of Sales -
Carrie Mendivil,
Head of Investor Relations -
James M Sullivan,
Director -
Cheryl R Blanchard,
Director -
Brian D. Baker,
VP, Global Operations -
Richard E Caruso,
10% owner -
Shweta Maniar,
Director -
Life Sciences Corp Integra ...,
-
Beau Standish,
President, Enabling Tech -
Angela Steinway,
Director